Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-HERCULES long-term follow-up of caplacizumab in thrombotic thrombocytopenic purpura
NL-OMON43030Phase 3Not yet recruiting
- Sponsor
- Ablynx
- Start
- Jan 2017
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Ablynx. Primary endpoints: TTP-related events, Mortality rate and 5 more. Planned start Jan 2017; status: not yet recruiting.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NL-OMON43030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43030.